GOTHENBURG, Sweden, April 12, 2010 PharmaSurgics inSweden AB - part of the Karolinska Development dermatology and wound healingcompany "Pergamum" - has received approval from the Danish Medicines Agencyand the Independent Ethics Committee to begin a phase II clinical trial inDenmark. The trial will monitor efficacy and safety of PharmaSurgics' novelcandidate drug PXL01 for the prevention of post-surgical adhesions inpatients undergoing hand surgery.
PharmaSurgics' Managing Director, Margit Mahlapuu said "In Sweden thetrial was initiated in December 2009 and the first patients have already beenenrolled. Extending the study to Danish centers is an important milestone forour ongoing clinical program."
PharmaSurgics has developed an interesting and novel approach in a marketwith significant unmet medical needs. Success in the Phase IIproof-of-concept study will enable the development of similar treatments fora broad range of surgical procedures.
The Phase II clinical trial will monitor the safety and document theefficacy of PXL01 in reducing adhesion formation following flexor tendonrepair surgery. This indication allows for measurement of objectiveendpoints, rather than subjective measurements of pain. The objective of theefficacy part of the study is to see an improvement in finger mobilitycompared to placebo following surgery.
About PharmaSurgics AB
PharmaSurgics in Sweden AB is a Gothenburg based biotech company thatdevelops and commercializes a novel treatment for preventing harmful scarringand promoting wound healing after surgery. PharmaSurgics product concept isbased on proprietary synthetic peptides which have strong anti-inflammatoryand anti-infectious properties. The company was founded in 2005, based onextensive research by Dr. Inger Mattsby- Baltzer and Professor Kjell Olmarkerat Sahlgrenska University Hospital, Goteborg, Sweden. PharmaSurgics is aKarolinska Development portfolio company. http://www.pharmasurgics.se/
About Karolinska Development AB (publ)
Karolinska Development manages one of the largest portfolios of lifescience companies in Europe.
Using a unique, highly cost efficient business model, the management teamguides the commercialization of world class life science innovations, helpingto shape the next generation pharma industry. Since 2003, KarolinskaDevelopment has built a portfolio of some 40 companies; among the company'sprojects 12 compounds are undergoing clinical trials. The portfolio alsoincludes a total of 21 potential first in class products.http://www.karolinskadevelopment.comFor further information, please contact: Margit Mahlapuu, Managing Director, PharmaSurgics in Sweden AB Phone: +46-(0)31-762-29-02 / Mobile: +46-(0)706-310-109 E-mail: firstname.lastname@example.org Jorgen Thorball, Chairman, Pergamum AB Phone: +45-(0)307-786-27 E-mail: email@example.com Conny Bogentoft, CEO, Karolinska Development AB Phone: +46-(0)70-668-61-43 E-mail: firstname.lastname@example.org
SOURCE PharmaSurgics AB and Karolinska Development AB